Loading organizations...
Key people at RBV Capital.
RBV Capital operates as a dedicated venture fund, specializing exclusively in the life sciences sector. It invests in a diversified portfolio across pharmaceuticals, biologics, digital healthcare products, and medical devices. The firm targets innovations addressing unmet medical needs, focusing on solutions with global outreach potential to advance patient care.
Established in 2014, RBV Capital was co-founded by key partners including Robert Karl and Arseniy Shabashvili, leveraging their extensive venture experience. Their insight identified the critical need to back promising early-stage companies poised for groundbreaking healthcare advancements. The firm’s origin reflects commitment to high-impact scientific innovation.
RBV Capital primarily supports innovative companies developing disruptive solutions within the life sciences arena. Its mission is to accelerate the introduction of vital healthcare technologies and therapies. The firm envisions its portfolio companies meaningfully improving global patient outcomes, fostering a more robust and advanced health ecosystem.
Key people at RBV Capital.
RBV Capital has 2 tracked investments across 2 companies. The latest tracked deal is $32.0M Series B in Pipeline Therapeutics in December 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2019 | Pipeline Therapeutics | $32.0M Series B | Stefan Larson | Buff Gold Ventures, Versant Ventures, Hadean Ventures |
| Jan 3, 2019 | Immusoft | $20.0M Series B | — | Alexandria Venture Investments, Breakout Ventures, DEFTA Partners, Mesa Verde Venture Partners |
